Idecabtagene-vicleucel: Cytokine-release-syndrome and tumour-lysis.

In a cohort study of 603 patients with relapsed/refractory multiple myeloma (RRMM), two patients experienced serious adverse events while receiving treatment with idecabtagene-vicleucel. One patient developed cytokine release syndrome (CRS) and the other experienced tumor lysis. Unfortunately, both patients died as a result of these complications. The specific details of the patients' ages, sexes, dosages, and routes of administration were not provided in the article. [Extracted from the article]